Fintel reports that on October 10, 2025, Canaccord Genuity maintained coverage of InMode (NasdaqGS:INMD) with a Hold recommendation. Analyst Price Forecast Suggests 8.62% Upside As of September 30, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Miami investor is pressing an ...
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable ...
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable ...
InMode saw 0 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See InMode’s stock price’s past reactions to earnings here. According to InvestingPro, InMode’s Financial Health ...
YOKNEAM, Israel, May 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital ...
IRVINE, Calif., May 6, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, reports that the US District Court for the Central District of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback